Long-acting injectable formulations of new-generation antipsychotics: A review from a clinical perspective

CNS Drugs

Volumn 27, Issue 8, 2013, Pages 637-652

  Rauch, Anna Sophia ^a   Fleischhacker, W Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; RISPERIDONE;

AGITATION; BIOEQUIVALENCE; CLINICAL GLOBAL IMPRESSION SCALE; CONCEPT FORMATION; DELTOID MUSCLE; DIZZINESS; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; GLUTEUS MAXIMUS MUSCLE; HEADACHE; HUMAN; INJECTION SITE PAIN; INSOMNIA; LIMB PAIN; MAINTENANCE THERAPY; MEDICATION COMPLIANCE; MENTAL CAPACITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; REVIEW; RHINOPHARYNGITIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 84880792676     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0083-9     Document Type: Review

References (101)

1. Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2010;71(Suppl 2):20-6.
2. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med. 2003;33(1):83-9.
3. Heres S, Hamann J, Kissling W, et al. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry. 2006;67(12):1948-53.
4. Harrison TS, Goa KL. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs. 2004;18(2):113-32.
5. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125-32.
6. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharm. 2005;15(1):111-7.
7. Turner M, Eerdekens E, Jacko M, et al. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol. 2004;19(4):241-9.
8. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003;64(10):1250-7.
9. Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatr Suppl. 2009;52:S29-36.
10. Fleischhacker WW, Gopal S, Lane R, et al. A Randomized Trial of Paliperidone Palmitate and Risperidone Long-Acting Injectable in Schizophrenia. Int J Neuropsychopharmacol. p. 1-12. [Epub 2011 Jul 22].
11. Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Progress Neuro-Psychopharm. 2011;35(1):218-26.
12. Macfadden W, Ma YW, Thomas Haskins J, et al. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry. 2010;7(11):23-31.
13. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76.
14. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441-9.
15. Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010;35(12):2367-77.
16. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New Engl J Med. 2002;346(1):16-22.
17. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New Engl J Med. 2011;364(9):842-51.
18. Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323-9.
19. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177-83.
20. Quiroz JA, Rusch S, Thyssen A, et al. Deltoid Injections of risperidone long-acting injectable in patients with schizophrenia. Innov Clin Neurosci. 2011;8(6):20-8.
21. Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic schizophrenia treatment adherence registry (e-STAR). Eur Psychiatry. 2009;24(5):287-96.
22. Guy W. Ecdeu assessment manual for psychopharmacology. Revised ed. Rockville, MD: National Institute of Mental Health; 1976. p. 218-22.
23. Endicott J, Spitzer RL, Fleiss JL, et al. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33(6):766-71.
24. Macfadden W, DeSouza C, Crivera C, et al. Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the source study results. BMC Psychiatry. 2011;11:167.
25. Strauss JS, Carpenter WT. Prediction of outcome in schizophrenia: III. Five-year outcome and its predictors. Arch Gen Psychiatry. 1977;34(2):159-63.
26. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;30(6):473-83.
27. Lambert T, Olivares JM, Peuskens J, et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry. 2011;10:10.
28. Covell NH, McEvoy JP, Schooler NR, et al. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. J Clin Psychiatry. 2012;73(5):669-75. [Epub 2012 March 6].
29. Weiden PJ, Schooler NR, Weedon JC, et al. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry. 2009;70(10):1397-406.
30. Weiden P, Rapkin B, Mott T, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull. 1994;20(2):297-310.
31. Emsley R, Oosthuizen P, Koen L, et al. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol. 2008;23(6):325-31.
32. Grimaldi-Bensouda L, Rouillon F, Astruc B, et al. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the cohort for the general study of schizophrenia (CGS). Schizophr Res. 2012;134(2-3):187-94.
33. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl. 20:22-33;quiz 4-57.
34. Wiffen BD, Rabinowitz J, Fleischhacker WW, et al. Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder. Clin Schizophr Relat Psychoses. 2010;4(3):169-75.
35. Mintz AR, Addington J, Addington D. Insight in early psychosis: a 1-year follow-up. Schizophr Res. 2004;67(2-3):213-7.
36. Lysaker PH, Bell MD, Bryson G, et al. Personality as a predictor of the variability of insight in schizophrenia. J Nerv Ment Dis. 1999;187(2):119-22.
37. Parellada E, Kouniakis F, Siurkute A, et al. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. Int Clin Psychopharmacol. 2010;25(3):149-54.
38. Rossi A, Bagala A, Del Curatolo V, et al. Remission in schizophrenia: one-year italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Hum Psychopharmacol. 2009;24(7):574-83.
39. Emsley R, Oosthuizen PP, Koen L, et al. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiatry. 2012;73(4):e541-7.
40. Lloyd K, Latif MA, Simpson S, et al. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. Hum Psychopharmacol. 2010;25(3):243-52.
41. Schmauss M, Diekamp B, Gerwe M, et al. Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia? Pharmacopsychiatry. 2010;43(2):73-80.
42. Lindenmayer JP, Eerdekens E, Berry SA, et al. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry. 2004;65(8):1084-9.
43. Moller HJ, Llorca PM, Sacchetti E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol. 2005;20(3):121-30.
44. Llorca PM, Sacchetti E, Lloyd K, et al. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. Int J Clin Pharmacol Ther. 2008;46(1):14-22.
45. Kissling W, Glue P, Medori R, et al. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. Hum Psychopharmacol. 2007;22(8):505-13.
46. Taylor D, Fischetti C, Sparshatt A, et al. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand. 2009;120(2):97-101.
47. Carswell C, Wheeler A, Vanderpyl J, et al. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis. Clin Drug Investig. 2010;30(11):777-87.
48. De la Gandara J, San Molina L, Rubio G, et al. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the sphere study. Expert Rev Neurother. 2009;9(10):1463-74.
49. Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603-9.
50. Thyssen A, Rusch S, Herben V, et al. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients. J Clin Pharmacol. 2010;50(9):1011-21.
51. Bartzokis G, Lu PH, Amar CP, et al. Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophr Res. 2011;132(1):35-41.
52. Surguladze SA, Chu EM, Marshall N, et al. Emotion processing in schizophrenia: fMRI study of patients treated with risperidone long-acting injections or conventional depot medication. J Psychopharmacol. 2011;25(6):722-33.
53. Morris JS, Frith CD, Perrett DI, et al. A differential neural response in the human amygdala to fearful and happy facial expressions. Nature. 1996;383(6603):812-5.
54. Phillips ML, Young AW, Senior C, et al. A specific neural substrate for perceiving facial expressions of disgust. Nature. 1997;389(6650):495-8.
55. Doknic M, Maric NP, Britvic D, et al. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology. 2011;94(3):246-54.
56. Rabinowitz J, Napryeyenko O, Burba B, et al. Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable. J Clin Psychopharmacol. 2011;31(1):75-81.
57. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8(3):470-84.
58. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62(12):1363-70.
59. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007;93(1-3):117-30.
60. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007;27(1):6-14.
61. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90(1-3):147-61.
62. Citrome L. Paliperidone palmitate: review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract. 2010;64(2):216-39.
63. Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia: results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010;13(5):635-47.
64. Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol. 2010;25(5):247-56.
65. Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2-3):107-17.
66. Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol. 2011;25(5):685-97.
67. Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010;35(10):2072-82.
68. Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30(3):235-44.
69. Li H, Rui Q, Ning X, et al. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1002-8.
70. Hough D, Lindenmayer JP, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(6):1022-31.
71. Alphs L, Bossie CA, Sliwa JK, et al. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry. 2011;10(1):12.
72. Bossie CA, Sliwa JK, Ma YW, et al. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial. BMC Psychiatry. 2011;11:79.
73. Sliwa JK, Bossie CA, Ma YW, et al. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. Schizophr Res. 2011;132(1):28-34.
74. Gopal S, Pandina G, Lane R, et al. A post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia. Innov Clin Neurosci. 2011;8(8):26-33.
75. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet. 2009;48(9):585-600.
76. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6):553-64.
77. Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract. 2009;63(1):140-50.
78. Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69(5):790-9.
79. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167(2):181-9.
80. Ascher-Svanum H, Zhao F, Detke HC, et al. Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia. BMC Psychiatry. 2011;11:152.
81. Witte MM, Case MG, Schuh KJ, et al. Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia. Curr Med Res Opin. 2012;28(3):315-23.
82. McDonnell DP, Kryzhanovskaya LA, Zhao F, et al. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine. Hum Psychopharmacol. 2011;26(6):422-33.
83. Hill AL, Sun B, Karagianis JL, et al. Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. BMC Psychiatry. 2011;11:28.
84. Detke HC, Zhao F, Garhyan P, et al. Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching. Int Clin Psychopharmacol. 2011;26(1):35-42.
85. Detke HC, McDonnell DP, Brunner E, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection: I. Analysis of cases. BMC Psychiatry. 2010;10:43.
86. McDonnell DP, Detke HC, Bergstrom RF, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection: II. Investigations of mechanism. BMC Psychiatry. 2010;10:45.
87. Ascher-Svanum H, Peng X, Montgomery W, et al. Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia. Eur Psychiatry. 2011;26(5):313-9.
88. Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology. 2008;33(2):298-304.
89. Fleischhacker WW. Aripiprazole. Expert Opin Pharmacother. 2005;6(12):2091-101.
90. Sanford M, Scott LJ. Intramuscular aripiprazole: a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS Drugs. 2008;22(4):335-52.
91. Fleischhacker W. Pharmacokinetic study of once-monthly aripiprazole intramuscular depot in adult patients with schizophrenia [poster]. In: 164th annual meeting of the American Psychiatric Association; 2011 May 14-18; Honolulu.
92. Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(5):617-24.
93. Guy W. AIMS: ECDEU assessment manual for psychopharmacology. Washington, DC: Government Printing Office; 1976.
94. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-9.
95. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-6.
96. Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for the treatment of schizophrenia: a double-blind, randomized, non-inferiority study vs. oral aripiprazole. Poster presented at the ACNP 2012 Annual Meeting, Dec 2012, Hollywood, FL.
97. Kwatra SG, Batson NE, Kramer SI. Long-acting risperidone and oral antipsychotics in schizophrenia. New Engl J Med. 2011;364(23):2264-5 author reply 265-6.
98. Suzuki T. Long-acting risperidone and oral antipsychotics in schizophrenia. N Engl J Med. 2011;364(23):2265 author reply 265-6.
99. Keks NA, Ingham M, Khan A, et al. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: randomised, controlled, open-label study. Br J Psychiatry. 2007;191:131-9.
100. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia: a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1-3):83-92.
101. Heres S, Schmitz FS, Leucht S, et al. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007;22(5):275-82.